Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Summary

The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.

Timeline

Start

2026-01-07

Primary completion

2029-06

Completion

2029-08

Drugs

Indications